Table 2.

Other efficacy and safety outcomes.

	≥50% reduction in average number of migraine days per month	Mean monthly days with acute headache medications, baseline to week 12	Mean monthly headache days, baseline to week 4	Mean monthly migraine days, baseline to week 4	Injection-site reactions	Infections	Dizziness or Nausea
	RR, 95% CI	MD, 95% CI	MD, 95% CI	MD, 95% CI	RR, 95% CI	RR, 95% CI	RR, 95% CI
Bigal (18)	NA	−2.10 (−4.26, 0.06)	−2.40 (−4.16, −0.64)	−2.50 (−4.07, −0.93)	3.21 (1.29, 7.96)	1.03 (0.40, 2.67)	NA
Bigal (21)	1.90 (1.34, 2.68)	−1.70 (−2.88, −0.52)	−1.70 (−2.88, −0.52)	−2.30 (−3.48, −1.12)	1.64 (0.84, 3.22)	1.09 (0.59, 2.04)	0.96 (0.29, 3.20)
Silberstein et al. (22)	2.17 (1.72, 2.74)	−2.10 (−2.69, −1.51)	−2.40 (−3.18, −1.62)	NA	1.12 (1.03, 1.22)	0.90 (0.64, 1.27)	0.93 (0.51, 1.68)
Dodick et al. (23)	1.65 (1.34, 2.03)	−1.30 (−1.69, −0.91)	NA	−1.70 (−2.29, −1.11)	1.26 (1.13, 1.41)	1.06 (0.74, 1.51)	1.11 (0.39, 3.16)
Ferrari et al. (24)	3.99 (2.68, 5.95)	−3.30 (−3.89, −2.71)	−3.80 (−4.58, −3.02)	−3.50 (−4.28, −2.72)	1.24 (0.91, 1.70)	0.94 (0.61, 1.46)	0.83 (0.37, 1.88)
Total	2.22 (1.60, 3.07) P < 0.001	−2.11 (−3.01, −1.21) P < 0.001	−2.65 (−3.63, −1.66) P < 0.001	−2.49 (−3.47, −1.51) P < 0.001	1.24 (1.07, 1.43) P = 0.003	0.98 (0.81, 1.20) P = 0.86	0.93 (0.62, 1.40) P = 0.73